Please login to the form below
lung cancer
This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer,” he added. ... the treatment of patients with metastatic non-small cell lung
Latest news
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. ... study. In a statement, AZ said that approximately a fifth of global
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung cancer (NSCLC).
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Roche’s immunotherapy Tecentriq has shown the first clinical improvement in post-surgery non-small cell lung cancer (NSCLC) although its benefit is limited to certain patients. ... This] landmark phase 3 data demonstrate[s] for the first time that
-
GSK discontinues two feladilimab trials in head and neck cancer
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
GSK discontinues two feladilimab trials in head and neck cancer
More from news
Approximately 111 fully matching, plus 851 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced non-small-cell lung cancer by four to five
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
The promise of precision medicine
Successful product commercialisation: what can we learn from the rare disease setting?
Growing evidence supports the important role of biosimilars in healthcare
Unlocking the potential of precision medicine in oncology
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
More from intelligence
Approximately 1 fully matching, plus 62 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
-
Iris Pauporté joins OSE Immunotherapeutics
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
-
Merck appoints ex-Pfizer exec as global head of oncology
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Astellas bolsters oncology clinical development leadership
Iris Pauporté joins OSE Immunotherapeutics
Astellas promotes John Demaree
Merck appoints ex-Pfizer exec as global head of oncology
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
-
September 2020: diversity and inclusion in clinical trials round-up
The Hispanic population is underrepresented in lung cancer trials despite experiencing different health outcomes to white people. ... The Hispanic population is generally not represented in lung cancer trials because of limited access and few research
-
July 2020: diversity and inclusion in clinical trials round-up
Black people are among those who typically suffer poorer health outcomes from lung cancer. ... Early next year, a Stand Up To Cancer Innovation Summit will launch the project, which will bring together lung cancer experts with researchers specializing in
-
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. ... 2017 Jul 11; 318(2):197-198. Denis F, Basch E et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine
September 2020: diversity and inclusion in clinical trials round-up
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 3 fully matching, plus 17 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
-
Senior Account Manager
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
-
Planner
-
Salary TBC
-
Publications Director
-
Competitive Salary
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- US announces $3bn funding boost for antiviral COVID-19 treatments
- Biogen doses first patient in phase 3 systemic lupus erythematosus study
- Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
- ‘Funny’, ha ha: how neurodiverse comedy can help us understand each other
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Packer Forbes acquired by Four Communications
- AI is transforming pharma R&D – now it can transform pharma marketing
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- How early-stage clinical research is facilitating the new wave of personalised medicines
- By Jorg Taubel...
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
- Why empathy in digital patient recruitment is vital
- This is where empathy mapping can be incredibly effective....
